Publications

Export 1384 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
Abdul Ghaffar Solangi, Aneela Tahira, A. S. C. T. P. Z. A. S. F. C., S. K. A. H. E. D. Muhammad Ali Bhatti, Adeel Liaquat Bhatti, A. A. K. H. Ismail, S. S. Medany, A. Nafady, L. V. Kangle, B. Vigolo, and Z. H. Ibupoto, "Enhanced electro active properties of NiCo2O4 nanostructures using garlic extract for the sensitive and selective enzyme-free detection of ascorbic acid", Journal of Materials Science: Materials in Electronics, vol. 34, issue 20, pp. 1549, 2023.
G, M., C. R, M. H. DM, G. D, M. MJ, M. D, O. D, R. K, R. P, S. EH, et al., "Enhanced interpretation of newborn screening results without analyte cutoff values.", Genet Med., vol. 7, issue 14, pp. 648-55, 2012.
Veys, K. R. P., M. A. Elmonem, F. Dhaenens, M. van Dyck, M. M. C. H. Janssen, E. A. M. Cornelissen, K. Hohenfellner, A. Reda, P. Quatresooz, B. van den Heuvel, et al., "Enhanced Intrinsic Skin Aging in Nephropathic Cystinosis Assessed by High-Definition Optical Coherence Tomography.", The Journal of investigative dermatology, 2019 Apr 22. Abstract
n/a
Elkhatib, T. A., V. Y. Kachorovskii, W. J. Stillman, D. B. Veksler, K. N. Salama, X. - C. Zhang, and M. S. Shur, "Enhanced plasma wave detection of terahertz radiation using multiple high electron-mobility transistors connected in series", IEEE Transactions on Microwave Theory and Techniques, vol. 58, issue 2: IEEE, pp. 331-339, 2010. Abstract
n/a
Biccard, B. M., L. du Toit, M. Lesosky, T. Stephens, L. Myer, A. B. A. Prempeh, N. Vickery, H. - L. Kluyts, A. Torborg, A. Omigbodun, et al., Enhanced postoperative surveillance versus standard of care to reduce mortality among adult surgical patients in Africa (ASOS-2): a cluster-randomised controlled trial, , vol. 9, issue 10, pp. e1391 - e1401, 2021. AbstractWebsite

SummaryBackground
Risk of mortality following surgery in patients across Africa is twice as high as the global average. Most of these deaths occur on hospital wards after the surgery itself. We aimed to assess whether enhanced postoperative surveillance of adult surgical patients at high risk of postoperative morbidity or mortality in Africa could reduce 30-day in-hospital mortality.
Methods
We did a two-arm, open-label, cluster-randomised trial of hospitals (clusters) across Africa. Hospitals were eligible if they provided surgery with an overnight postoperative admission. Hospitals were randomly assigned through minimisation in recruitment blocks (1:1) to provide patients with either a package of enhanced postoperative surveillance interventions (admitting the patient to higher care ward, increasing the frequency of postoperative nursing observations, assigning the patient to a bed in view of the nursing station, allowing family members to stay in the ward, and placing a postoperative surveillance guide at the bedside) for those at high risk (ie, with African Surgical Outcomes Study Surgical Risk Calculator scores ≥10) and usual care for those at low risk (intervention group), or for all patients to receive usual postoperative care (control group). Health-care providers and participants were not masked, but data assessors were. The primary outcome was 30-day in-hospital mortality of patients at low and high risk, measured at the participant level. All analyses were done as allocated (by cluster) in all patients with available data. This trial is registered with ClinicalTrials.gov, NCT03853824.
Findings
Between May 3, 2019, and July 27, 2020, 594 eligible hospitals indicated a desire to participate across 33 African countries; 332 (56%) were able to recruit participants and were included in analyses. We allocated 160 hospitals (13 275 patients) to provide enhanced postoperative surveillance and 172 hospitals (15 617 patients) to provide standard care. The mean age of participants was 37·1 years (SD 15·5) and 20 039 (69·4%) of 28 892 patients were women. 30-day in-hospital mortality occurred in 169 (1·3%) of 12 970 patients with mortality data in the intervention group and in 193 (1·3%) of 15 242 patients with mortality data in the control group (relative risk 0·96, 95% CI 0·69–1·33; p=0·79). 45 (0·2%) of 22 031 patients at low risk and 309 (5·6%) of 5500 patients at high risk died. No harms associated with either intervention were reported.
Interpretation
This intervention package did not decrease 30-day in-hospital mortality among surgical patients in Africa at high risk of postoperative morbidity or mortality. Further research is needed to develop interventions that prevent death from surgical complications in resource-limited hospitals across Africa.
Funding
Bill & Melinda Gates Foundation and the World Federation of Societies of Anaesthesiologists.
Translations
For the Arabic, French and Portuguese translations of the abstract see Supplementary Materials section.

de la Puente, P., M. J. Luderer, C. Federico, A. Jin, R. C. Gilson, C. Egbulefu, K. Alhallak, S. Shah, B. Muz, J. Sun, et al., "Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.", Journal of controlled release : official journal of the Controlled Release Society, vol. 270, pp. 158-176, 2017 Nov 28, 2018. Abstractj_of_controlled_release_2018.pdf

The establishment of more effective treatments that can circumvent chemoresistance in Multiple Myeloma (MM) is a priority. Although bortezomib (BTZ) is one of the most potent proteasome inhibitors available, still possesses limitations related to dose limiting side effects. Several strategies have been developed to improve the delivery of chemotherapies to MM by targeting different moieties expressed on MM cells to nanoparticle delivery systems (NPs), which have failed mainly due to their heterogeneous expression on these cells. Our goal was to test CD38 targeted chitosan NPs as novel targeting moiety for MM to improve the potency and efficacy of BTZ in MM cells and reduce the side effects in healthy tissue. We have showed preferential BTZ release in tumor-microenvironment, specific binding to MM cells, and an improved drug cellular uptake through BTZ diffusion from the surface and endocytosed NPs, which translated in enhanced proteasome inhibition and robust cytotoxic effect on MM cells when BTZ was administered through anti-CD38 chitosan NPs. Furthermore, the anti-CD38 chitosan NPs specifically delivered therapeutic agents to MM cells improving therapeutic efficacy and reducing side effects in vivo. The anti-CD38 chitosan NPs showed low toxicity profile allowing enhancement of proteasome-inhibitory activity and specificity of BTZ by endocytosis-mediated uptake of CD38 representing a promising therapy in MM.

Brito-Zerón, P., N. Acar-Denizli, W. - F. Ng, I. F. Horváth, A. Rasmussen, R. Seror, X. Li, C. Baldini, J. - E. Gottenberg, D. Danda, et al., "Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome.", Rheumatology (Oxford, England), vol. 59, issue 9, pp. 2350-2359, 2020. Abstract

OBJECTIVE: To characterize the systemic phenotype of primary Sjögren's syndrome at diagnosis by analysing the EULAR-SS disease activity index (ESSDAI) scores.

METHODS: The Sjögren Big Data Consortium is an international, multicentre registry based on worldwide data-sharing cooperative merging of pre-existing databases from leading centres in clinical research in Sjögren's syndrome from the five continents.

RESULTS: The cohort included 10 007 patients (9352 female, mean 53 years) with recorded ESSDAI scores available. At diagnosis, the mean total ESSDAI score was 6.1; 81.8% of patients had systemic activity (ESSDAI score ≥1). Males had a higher mean ESSDAI (8.1 vs 6.0, P < 0.001) compared with females, as did patients diagnosed at <35 years (6.7 vs 5.6 in patients diagnosed at >65 years, P < 0.001). The highest global ESSDAI score was reported in Black/African Americans, followed by White, Asian and Hispanic patients (6.7, 6.5, 5.4 and 4.8, respectively; P < 0.001). The frequency of involvement of each systemic organ also differed between ethnic groups, with Black/African American patients showing the highest frequencies in the lymphadenopathy, articular, peripheral nervous system, CNS and biological domains, White patients in the glandular, cutaneous and muscular domains, Asian patients in the pulmonary, renal and haematological domains and Hispanic patients in the constitutional domain. Systemic activity measured by the ESSDAI, clinical ESSDAI (clinESSDAI) and disease activity states was higher in patients from southern countries (P < 0.001).

CONCLUSION: The systemic phenotype of primary Sjögren's syndrome is strongly influenced by personal determinants such as age, gender, ethnicity and place of residence, which are key geoepidemiological players in driving the expression of systemic disease at diagnosis.

Abdel-Hakeem, M. S., S. Manne, J. - C. Beltra, E. Stelekati, Z. Chen, K. Nzingha, M. - A. Ali, J. L. Johnson, J. R. Giles, D. Mathew, et al., "Epigenetic scarring of exhausted T cells hinders memory differentiation upon eliminating chronic antigenic stimulation.", Nature immunology, vol. 22, issue 8, pp. 1008-1019, 2021. Abstract

Exhausted CD8 T cells (T) are a distinct state of T cell differentiation associated with failure to clear chronic viruses and cancer. Immunotherapies such as PD-1 blockade can reinvigorate T cells, but reinvigoration is not durable. A major unanswered question is whether T cells differentiate into functional durable memory T cells (T) upon antigen clearance. Here, using a mouse model, we found that upon eliminating chronic antigenic stimulation, T cells partially (re)acquire phenotypic and transcriptional features of T cells. These 'recovering' T cells originated from the T cell factor (TCF-1) T progenitor subset. Nevertheless, the recall capacity of these recovering T cells remained compromised as compared to T cells. Chromatin-accessibility profiling revealed a failure to recover core memory epigenetic circuits and maintenance of a largely exhausted open chromatin landscape. Thus, despite some phenotypic and transcriptional recovery upon antigen clearance, exhaustion leaves durable epigenetic scars constraining future immune responses. These results support epigenetic remodeling interventions for T cell-targeted immunotherapies.

Mohamed, G., P. Murray, E. Nagy, and K. Vrzalikova, "Epstein–Barr virus, the germinal centre and the development of Hodgkin’s lymphoma", Journal of General Virology, vol. 95, issue 10.1099/vir.0.066712-0, pp. 1861–1869, Submitted. 1861.full_.pdf
Elkadi, H., J. P. Vilcot, and D. Decoster, "An equivalent circuit model for multielectrode lasers: Potential devices for millimeter-wave applications", Microwave and Optical Technology Letters, vol. 6, no. 4: Wiley Online Library, pp. 245–249, 1993. Abstract
n/a
Clemente, C. S., A. Mahgoub, D. Davino, and C. Visone, EQUIVALENTE 3-PORTE DI UN DISPOSITIVO DI ENERGY HARVESTING, , Submitted. Abstract
n/a
Clemente, C. S., A. Mahgoub, D. Davino, and C. Visone, EQUIVALENTE 3-PORTE DI UN DISPOSITIVO DI ENERGY HARVESTING, , 2016. Abstract

n/a

Lotfi, M. A., J. Varga, and I. H. Hirsch, "Erectile dysfunction in systemic sclerosis.", Urology, vol. 45, issue 5, pp. 879-81, 1995. Abstract

Systemic sclerosis (SSc, scleroderma), a connective tissue disorder involving multiple organ systems, can be a causal factor in erectile dysfunction. We present a case report and a review of the literature. Awareness of this association can hasten the detection of this disorder and influence management choices.

Abdelrahman, H., M. Elhady, A. Alcivar-Warren, S. Allen, R. Al-Tobasei, L. Bao, B. Beck, H. Blackburn, B. Bosworth, J. Buchanan, et al., "Erratum to: Aquaculture genomics, genetics and breeding in the United States: current status, challenges, and priorities for future research.", BMC genomics, vol. 18, issue 1, pp. 235, 2017 03 16.
Lyons, I., D. Furniss, A. Blandford, G. Chumbley, I. Iacovides, L. Wei, A. Cox, A. Mayer, J. Vos, G. H. Galal-Edeen, et al., "Errors and discrepancies in the administration of intravenous infusions: a mixed methods multihospital observational study", BMJ Qual Saf, vol. 27, no. 11, pp. 892–901, 2018. Abstract
n/a
Bielczyk, N., M. Veldsman, A. Ando, C. Caldinelli, M. M. Makary, A. Nikolaidis, M. A. Scelsi, M. Stefan, and A. P. Badhwar, "Establishing online mentorship for early career researchers: Lessons from the Organization for Human Brain Mapping International Mentoring Programme.", The European journal of neuroscience, vol. 49, issue 9, pp. 1069-1076, 2019. Abstract

Mentorship facilitates personal growth through pairing trainees with mentors who can share their expertise. In times of global integration, geographical proximity between mentors and mentees is relevant to a lesser degree. This has led to popularization of online mentoring programs. In this editorial, we introduce the history and architecture of the International Online Mentoring Programme organized by the Student and Postdoc Special Interest Group of the Organization for Human Brain Mapping.

Nazier, H., R. Assaad, R. Ramadan, C. Krafft, A. Vahidmanesh, and S. Zouari, "Estimating Poverty and Inequality in the Absence of Consumption Data: An Application to the Middle East and North Africa", Middle East Development Journa, vol. 11, issue 1, pp. 1-29, 2019.
Enpuku, K., A. L. Elrefai, T. Yoshida, T. Kahmann, J. Zhong, T. Viereck, and F. Ludwig, "Estimation of the effective magnetic anisotropy constant of multi-core based magnetic nanoparticles from the temperature dependence of the coercive field", Journal of Applied Physics, vol. 127, no. 13, 2020. AbstractWebsite
n/a
Vázquez, H. C., A. M. I. R. EL SAYED, S. Y. B. I. L. L. E. JAGER, A. L. B. E. R. JOACHIM, C. R. I. S. T. O. P. H. LAMMLER, and W. I. L. F. R. I. E. D. WOTER, Estudio comparativo de las características de Staphylococcus aureus aislados de casos de mastitis clínica y subclínica en México, , vol. 37, issue 002, 2009. Abstract
n/a
Alber, J., H. C. Vázquez, A. M. I. R. EL SAYED, S. Jäger, C. Lämmler, and W. Wolter, Estudio comparativo de las características genotípicas de cepas de Staphylococcus aureus aisladas de casos de mastitis clínica y subclínica en México, : Universidad Nacional Autónoma de México, 2006. Abstract
n/a
Ramos-Casals, M., P. Brito-Zerón, S. Bombardieri, H. Bootsma, S. De Vita, T. Dörner, B. A. Fisher, J. - E. Gottenberg, G. Hernandez-Molina, A. Kocher, et al., "EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.", Annals of the rheumatic diseases, vol. 79, issue 1, pp. 3-18, 2020. Abstract

The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging in clinical practice, without a specific therapeutic target beyond the relief of symptoms as the most important goal. In view of this scenario, the European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing the first EULAR evidence and consensus-based recommendations for the management of patients with SjS with topical and systemic medications. The aim was to develop a rational therapeutic approach to SjS patients useful for healthcare professionals, physicians undergoing specialist training, medical students, the pharmaceutical industry and drug regulatory organisations following the 2014 EULAR standardised operating procedures. The Task Force (TF) included specialists in rheumatology, internal medicine, oral health, ophthalmology, gynaecology, dermatology and epidemiology, statisticians, general practitioners, nurses and patient representatives from 30 countries of the 5 continents. Evidence was collected from studies including primary SjS patients fulfilling the 2002/2016 criteria; when no evidence was available, evidence from studies including associated SjS or patients fulfilling previous sets of criteria was considered and extrapolated. The TF endorsed the presentation of general principles for the management of patients with SjS as three overarching, general consensus-based recommendations and 12 specific recommendations that form a logical sequence, starting with the management of the central triplet of symptoms (dryness, fatigue and pain) followed by the management of systemic disease. The recommendations address the use of topical oral (saliva substitutes) and ocular (artificial tear drops, topical non-steroidal anti-inflammatory drugs, topical corticosteroids, topical CyA, serum tear drops) therapies, oral muscarinic agonists (pilocarpine, cevimeline), hydroxychloroquine, oral glucocorticoids, synthetic immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, leflunomide and mycophenolate), and biological therapies (rituximab, abatacept and belimumab). For each recommendation, levels of evidence (mostly modest) and TF agreement (mostly very high) are provided. The 2019 EULAR recommendations are based on the evidence collected in the last 16 years in the management of primary 2002 SjS patients and on discussions between a large and broadly international TF. The recommendations synthesise current thinking on SjS treatment in a set of overarching principles and recommendations. We hope that the current recommendations will be broadly applied in clinical practice and/or serve as a template for national societies to develop local recommendations.

Hamed, A. M., E. Tsakali, E. - S. M. Abdeen, J. F. M. Van Impe, and H. A. Ismail, "Evaluation of the composition of colostrum and milk from various animal species in the desert climate of Egypt", Journal of Animal Behaviour and Biometeorology, vol. 11, no. 4, 2023. AbstractWebsite
n/a
Maggio, A., A. Kattamis, M. Felisi, G. Reggiardo, A. El-Beshlawy, M. Bejaoui, L. Sherief, S. Christou, C. Cosmi, O. Della Pasqua, et al., "Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.", The Lancet. Haematology, vol. 7, issue 6, pp. e469-e478, 2020. Abstract

BACKGROUND: Transfusion-dependent haemoglobinopathies require lifelong iron chelation therapy with one of the three iron chelators (deferiprone, deferasirox, or deferoxamine). Deferasirox and deferiprone are the only two oral chelators used in adult patients with transfusion-dependent haemoglobinopathies. To our knowledge, there are no randomised clinical trials comparing deferiprone, a less expensive iron chelator, with deferasirox in paediatric patients. We aimed to show the non-inferiority of deferiprone versus deferasirox.

METHODS: DEEP-2 was a phase 3, multicentre, randomised trial in paediatric patients (aged 1 month to 18 years) with transfusion-dependent haemoglobinopathies. The study was done in 21 research hospitals and universities in Italy, Egypt, Greece, Albania, Cyprus, Tunisia, and the UK. Participants were receiving at least 150 mL/kg per year of red blood cells for the past 2 years at the time of enrolment, and were receiving deferoxamine (<100 mg/kg per day) or deferasirox (<40 mg/kg per day; deferasirox is not registered for use in children aged <2 years so only deferoxamine was being used in these patients). Any previous chelation treatment was permitted with a 7-day washout period. Patients were randomly assigned 1:1 to receive orally administered daily deferiprone (75-100 mg/kg per day) or daily deferasirox (20-40 mg/kg per day) administered as dispersible tablets, both with dose adjustment for 12 months, stratified by age (<10 years and ≥10 years) and balanced by country. The primary efficacy endpoint was based on predefined success criteria for changes in serum ferritin concentration (all patients) and cardiac MRI T2-star (T2*; patients aged >10 years) to show non-inferiority of deferiprone versus deferasirox in the per-protocol population, defined as all randomly assigned patients who received the study drugs and had available data for both variables at baseline and after 1 year of treatment, without major protocol violations. Non-inferiority was based on the two-sided 95% CI of the difference in the proportion of patients with treatment success between the two groups and was shown if the lower limit of the two-sided 95% CI was greater than -12·5%. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with EudraCT, 2012-000353-31, and ClinicalTrials.gov, NCT01825512.

FINDINGS: 435 patients were enrolled between March 17, 2014, and June 16, 2016, 393 of whom were randomly assigned to a treatment group (194 to the deferiprone group; 199 to the deferasirox group). 352 (90%) of 390 patients had β-thalassaemia major, 27 (7%) had sickle cell disease, five (1%) had thalassodrepanocytosis, and six (2%) had other haemoglobinopathies. Median follow-up was 379 days (IQR 294-392) for deferiprone and 381 days (350-392) for deferasirox. Non-inferiority of deferiprone versus deferasirox was established (treatment success in 69 [55·2%] of 125 patients assigned deferiprone with primary composite efficacy endpoint data available at baseline and 1 year vs 80 [54·8%] of 146 assigned deferasirox, difference 0·4%; 95% CI -11·9 to 12·6). No significant difference between the groups was shown in the occurrence of serious and drug-related adverse events. Three (2%) cases of reversible agranulocytosis occurred in the 193 patients in the safety analysis in the deferiprone group and two (1%) cases of reversible renal and urinary disorders (one case of each) occurred in the 197 patients in the deferasirox group. Compliance was similar between treatment groups: 183 (95%) of 193 patients in the deferiprone group versus 192 (97%) of 197 patients in the deferisirox group.

INTERPRETATION: In paediatric patients with transfusion-dependent haemoglobinopathies, deferiprone was effective and safe in inducing control of iron overload during 12 months of treatment. Considering the need for availability of more chelation treatments in paediatric populations, deferiprone offers a valuable treatment option for this age group.

FUNDING: EU Seventh Framework Programme.

Chatrchyan, S., V. Khachatryan, A. M. Sirunyan, A. Tumasyan, W. Adam, E. Aguilo, T. Bergauer, M. Dragicevic, J. Erö, C. Fabjan, et al., "Evidence for associated production of a single top quark and W Boson in pp collisions at √s=7 TeV", Physical Review Letters, vol. 110, no. 2, 2013. AbstractWebsite
n/a
K, A., Salim Alhatrushi, Ali Al Buloshi, Fernando Domínguez-Castro, Noura Al Nasiri, S. M. Robaa, Talal Al Awadhi, Francisco Navarro-Serrano, P. - M. Schuwerack, and S. M. Vicente-Serrano, "Evidence for intensification of meteorological droughts in Oman over the past four decades", ATMOSPHERIC RESEARCH, vol. 246, 2020.
Tourism